Thanks ds for the link. One interesting point arising from the research paper;
Page 1 - Introduction: the point is made that with each of the collaboration agreements signed to date, AstraZeneca, Roche, Pfizer and J&J, that each can yield milestone payments in due course.
The inference appears to be that the collaborations are alive and active [rather than run their course and stalled]. What do we make of the language used in the research paper?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
0.015(1.19%) |
Mkt cap ! $746.5M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.28 | $1.27 | $194.9K | 153.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24574 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.28 | 17214 | 6 |
View Market Depth
| Last trade - 11.35am 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |